

Macular Degeneration

Macular Degeneration New Zealand

Macular Degeneration New Zealand (MDNZ) is a national charity that aims to reduce the incidence and impact of Macular Degeneration in New Zealand through awareness, education, client services and representation.

As a charity, MDNZ relies upon donations, bequests and fundraising to support its work. If you would like to donate to support MDNZ or arrange for a bequest please contact MDNZ.

Macular Degeneration New Zealand

PO Box 137070

Parnell

Auckland 1151

New Zealand

Phone: 0800 MACULA (0800 622 852)

E: info@mdnz.org.nz

W: www.mdnz.org.nz



MDNZ acknowledges the extensive support, assistance and cooperation of the Macular Disease Foundation Australia.

DISCLAIMER: Information contained in this fact sheet is considered by Macular Degeneration New Zealand (MDNZ) to be accurate at the time of publication. While every care has been taken in its preparation, medical advice should be sought from a doctor. MDNZ cannot be liable for any error or omission in this publication or for damages arising from its supply, performance or use, and makes no warranty of any kind, either expressed or implied in relation to this publication.

This brochure is produced by MDNZ. It is intended as a guide only and its contents do not constitute medical advice and should not be referred to as such.

Contents

Introduction.....	2
What is Macular Degeneration?	2
What is the macula?	2
How does the eye work?	3
How common is Macular Degeneration?	3
What causes Macular Degeneration?	3
What happens in Macular Degeneration?	3
How do I know if I have Macular Degeneration?	5
Detecting changes in vision	6
What tests are used to diagnose Macular Degeneration?	6
What treatment is available?	8
What can I do?	10
Coping with vision loss	11
MDNZ resources.....	12
Other resources	13
The Amsler Grid	Back cover

Introduction

Macular Degeneration (MD) is the leading cause of blindness and severe vision loss in New Zealand. This booklet provides information about MD. It explains MD and why the macula is important, describes how MD affects vision and how to reduce the risk of developing it. It also explains how to identify signs and symptoms of MD, treatments and support services available.

What is Macular Degeneration?

MD is the name given to a group of degenerative retinal eye diseases that cause progressive loss of central vision, leaving the peripheral or side vision intact. MD is associated with ageing and usually affects people over 50 years of age. It is commonly referred to as Age-related Macular Degeneration or AMD. However, inherited forms of the disease can also affect young people.


MD is progressive and painless and, although MD can lead to legal blindness, it does not result in total or black blindness.

What is the macula?

You are reading this using your macula.

The macula is the central area of the retina at the back of the eye. The macula is responsible for detailed central vision and most colour vision, the ability to read, recognise faces, drive a car, see colour clearly and other activities that require fine vision.

The rest of the retina is called the peripheral retina. It is used to see general shapes and provides get-about vision that is also called side or peripheral vision.



How does the eye work?

The eye works like an old style film camera. The front of the eye (cornea, pupil and lens) focuses an image on the retina that lines the back of the eye. The retina is light sensitive and acts like camera film in capturing the image. The image is then sent via the optic nerve to the brain where it is interpreted.

How common is Macular Degeneration?

One in seven New Zealanders (633,000) over the age of 50 has some evidence of MD. Approximately 17% of these people (108,000) experience vision impairment. MD is the leading cause of legal blindness in New Zealand and is responsible for nearly 50% of all cases of blindness.

What causes Macular Degeneration?

MD is caused by genetic and environmental factors. Risk factors include age, family history, smoking and diet and lifestyle factors.


The incidence of MD increases with age.

MD can be hereditary, with a 50% chance of inheriting the genetic predisposition if there is a positive family history of the disease. Since at least 70% of cases of MD have a genetic link, it is crucial that people with MD inform their siblings and children and encourage them to have their eyes, including the macula, checked.


Smokers are 3 to 4 times more likely to develop MD, and smokers may develop the disease 5 to 10 years earlier than non-smokers. Those with a specific genetic predisposition who smoke have a significantly increased risk of developing MD.

What happens in Macular Degeneration?

MD is a disease that affects a special layer of cells in the eye called the retinal pigment epithelium (RPE). The RPE is like a barrier that separates the retina from its main blood supply, a vascular layer called the choroid. The major role of the RPE is to nourish the retina and get rid of its waste products.



Early stages of Macular Degeneration



As MD progresses waste products from the retina build up underneath the RPE, forming yellow deposits called drusen. Drusen may be present without you knowing they are there. That is why it is important to have an eye test and the macula checked by an optometrist or eye specialist.

Early signs do not necessarily cause visual symptoms. Furthermore, not everyone with drusen will inevitably lose vision. However, the existence of drusen increases the chance of MD-associated vision loss.


Advanced MD is characterised by vision loss because the RPE cells die or because they fail to keep blood vessels in the choroid from growing under the retina.

Dry Macular Degeneration


When RPE cells die, the retinal cells above them also die leading to patches of missing retina. This is commonly called geographic atrophy or dry MD. Dry MD is slowly progressive and causes gradual loss of vision over several years. It accounts for 33% of all cases of advanced MD. Five to 10% of people who have dry MD can develop the more aggressive wet form.

Wet Macular Degeneration


Wet MD occurs when the RPE cells fail to stop choroidal blood vessels growing under the retina. This growth is called choroidal neovascularisation (CNV). The rapidly growing vessels are fragile with leaky walls and they ooze fluid and blood under the retina, leading to scarring and vision loss.



This is what drusen looks like in the eye.



This shows dry MD with patches of missing retina, pigment changes and drusen.



This shows wet MD with bleeding and scarring under the retina.

How do I know if I have Macular Degeneration?

Symptoms include one or more of the following:

- Distortion, where straight lines appear wavy or bent
- Difficulty reading or with any activity that requires fine vision
- Difficulty distinguishing faces
- Dark patches or empty spaces in the centre of the vision

With macular degeneration, print may appear distorted, and parts of words may be missing.

Blurred vision

Loss of contrast



The need for increased illumination, sensitivity to glare, decreased night vision and poor colour sensitivity may also indicate something is wrong. These symptoms should not be dismissed as simply part of getting older.

It is essential to have your eyes tested and the macula checked regularly by an eye care professional. However, you should arrange to see an eye specialist urgently if you experience any symptoms of MD or you are in any way concerned about your vision.


Early detection and prompt treatment are crucial to saving sight.

Detecting changes in vision


Any sudden changes in vision, or the development of symptoms, should be reported to an eye specialist immediately. An appointment should be obtained within a week. The earlier treatment is given, the more likely it is that vision can be saved. Delayed treatment increases the likelihood of losing sight.

The Amsler Grid

The Amsler Grid is an essential self-monitoring tool used to detect changes in vision. It is not a substitute for regular eye examinations. More information on the Amsler Grid is on the back cover of this booklet.



Normal vision



See an eye care professional

What tests are used to diagnose MD?

Eye examination


An eye care professional may use eye drops to dilate your pupils to allow a better view of the retina at the back of the eye. After dilation, the vision may be blurry for a few hours. You should not drive while the pupils are still dilated.

Amsler Grid

The Amsler Grid may be used to detect distortion in vision where straight lines appear wavy or bent and to see if there are dark spaces or empty patches in the vision.

Optical Coherence Tomography (OCT)


An OCT scan is a standard investigation for the diagnosis and ongoing management of wet MD. It is a non-invasive imaging technique that uses light to produce very high resolution cross sectional images of the retinal layers.



This OCT image of a patient with wet MD shows elevation of the retina due to fluid leaking underneath it. This image was originally published in the ASRS Retina Image Bank. Author: James Soque. Photographer: James Soque. Title: OCT Cirrus 5 line HD scan EDI ARMD SRF RPED stage 3 PVD. Retina Image Bank. 2013; 5064. © The American Society of Retina Specialists.

Fluorescein Angiogram

Fluorescein angiography is sometimes used to investigate wet MD. It involves injecting fluorescein dye into a vein in the arm to image the blood circulation at the back of the eye. As the dye circulates through the choroidal and retinal blood vessels, a camera with a special filter is used to take a series of photographs over about 10 minutes. The dye highlights any abnormalities or damage to the blood vessels.



This angiogram of a patient with wet MD shows new blood vessels that have formed and are leaking under the retina. This image was originally published in Retina Gallery. Author: Steven Cohen. Title: Classic subfoveal choroidal neovascular membrane – 6/120 vision. Retina Gallery. 2010.

What treatment is available?


Currently there are no medical treatments for dry MD. However, a considerable amount of research is being conducted to find a treatment.

There are a number of medical treatments available for wet MD. These treatments do not cure the disease but aim to stabilise vision and maintain the best vision for as long as possible. In some people, treatment can improve vision.

Anti-VEGF drugs

In wet MD, blood vessels are prompted to grow under the retina by a protein called vascular endothelial growth factor (VEGF). These vessels can bleed, leak fluid and cause scarring under the retina leading to rapid vision loss that becomes permanent if left untreated. To slow or stop this process, various drugs that block VEGF (called anti-VEGFs) can be used.

These drugs consist of an antibody directed at VEGF. They are injected into the eye, spread to the retina and block VEGF induced blood vessel growth. Anti-VEGF drugs have been proven effective in many clinical trials and maintain vision in the vast majority of patients with wet MD.



Treatment usually begins with monthly injections for 3 months. In order to maintain control of the disease, injections may be required indefinitely. However, the interval between injections is determined on an individualised basis by the eye specialist in consultation with the patient.

Avastin (bevacizumab)

Avastin was primarily developed, tested and approved to decrease new blood vessel growth associated with cancer. It is highly effective and used worldwide for treating wet MD. It is funded by PHARMAC, the New Zealand government agency that decides which medicines are subsidised for use in the community and public hospitals. However, it is not registered for the treatment of MD as it was not designed for use in the eye. Avastin is typically used as the initial treatment of wet MD in New Zealand.

Lucentis (ranibizumab)

Lucentis is very similar to Avastin. It is derived from the same parent molecule but is much smaller and has been pharmacologically altered to provide stronger binding to VEGF than Avastin. Lucentis was specifically formulated and registered for use in the eye. It costs significantly more than Avastin and its availability in the New Zealand public health service is restricted by PHARMAC.

Eylea (aflibercept)

Eylea is similar to Avastin and Lucentis but works slightly differently to them. It binds to VEGF significantly more strongly than both Avastin and Lucentis, and also binds placental growth factor (another factor involved in the development of abnormal blood vessels). It is longer acting and only needs to be injected every 2 to 3 months rather than monthly. It is registered for use in the eye but not funded by PHARMAC.

Treatment with injections

The choice of the most appropriate drug should be discussed with an eye specialist. Irrespective of which drug is used, the following is a general guide to treatment with eye injections.

- The eye is numbed with eye drops or local anaesthetic. The procedure is quick, relatively painless and usually carried out in the specialist's rooms, although some patients may be treated in a day stay unit.
- Appointments with an eye specialist should not be missed, even if there does not appear to be any problem with vision.
- Vision should continue to be monitored every day using an Amsler Grid. This is important for all injection schedules, including when the interval between injections is being increased or injections have ceased.
- Any sudden changes in vision should be reported to an eye specialist immediately, regardless of whether or not injections are being received. Do not wait for the next appointment.
- Even if vision has stabilised or improved, treatment may still need to be continued.
- Treatment should not stop unless on the advice of an eye specialist.
- Injections may be required indefinitely to maintain vision.
- If there are any concerns regarding coping with injections, or any difficulties following injection, it is important to raise these with the eye specialist.

Photodynamic Therapy (PDT)

This is a 2-step process combining a light-activated drug called Visudyne (verteporfin) with light from a cold laser directed onto the abnormal area of the retina. Once activated, the drug causes the abnormal vessels to close off. PDT does not cause direct damage to the surrounding retina. Therefore, it can be used to treat new vessels that are under the centre of the macula (fovea).


Several treatments are needed to keep the leaking blood vessels closed and stop the progression of wet MD. Close follow up and monitoring is needed to determine if further treatment is required.

Unlike treatment with anti-VEGF drugs that usually maintain vision, patients undergoing PDT continue to lose vision in the first 6 months before vision stabilises.

PDT is now rarely used to treat ordinary wet MD. It is sometimes used in conjunction with an anti-VEGF drug to treat a type of MD called polypoidal choroidal vasculopathy (PCV), as some of these cases do not settle completely with anti-VEGF treatment.

Laser photocoagulation

This treatment consists of a concentrated light beam of high-energy thermal light that is directed onto the retina to destroy and seal leaking blood vessels. It is not painful. The laser not only destroys the abnormal vessels but also destroys adjacent retina. Therefore, it may only be used for treating new vessels that are not under the central part of the macula.



Laser photocoagulation is only used for a small percentage of patients with wet MD. Close follow up is required as there is a 50% recurrence rate.

Treatment options for wet MD should be discussed with an eye specialist.

If you have private health insurance, please check your policy or with your insurer as treatment cover differs between companies.

What can I do?

Although age and family history cannot be changed, the following can help reduce the risk of MD and slow its progression.

- Don't smoke
- Eat a healthy, well-balanced diet
- Eat green leafy vegetables and fresh fruit daily
- Eat fish 2 to 3 times a week
- Choose low glycemic index (GI) carbohydrates instead of high GI
- Eat a handful of nuts a week
- Limit your intake of fats and oils
- Maintain a healthy lifestyle, control weight and exercise regularly
- Consider taking a supplement in consultation with your doctor



The Age Related Eye Disease Studies (AREDS 1 and 2) are two major clinical trials conducted by the National Eye Institute in the USA. The studies identified a specific formula of antioxidants including high dose zinc that significantly reduced the relative risk of progression of MD and delayed vision loss.

The daily amounts of these are:

Zinc	80 mg
Copper	2 mg
Vitamin E	400 IU
Vitamin C	500 mg
Lutein	10 mg
Zeaxanthin	2 mg



Any changes in diet or lifestyle should be undertaken in consultation with your doctor. More information is contained in MDNZ's Nutrition and Supplements fact sheet.

Coping with vision loss

The challenge

It takes time to adjust to vision loss. People experience different feelings from acceptance to disbelief. Some people experiencing vision loss for the first time may find daily activities challenging. However, with support, assistance and the right advice these challenges can be overcome to maintain quality of life and independence. The more a person knows about their condition, its effects and options for dealing with the challenges presented by low vision, the more confidence they will feel.

The low vision pathway

Moving forward with vision loss begins with taking control. A low vision assessment is the best way to get started. This enables people to find the best strategies and support options for their individual needs. Low vision support utilises advice on appropriate lighting, visual aids and technology to provide solutions for managing daily tasks.

A positive attitude, perseverance and the ability to seek help and support has enabled many people with low vision to fulfil their aspirations and maintain their quality of life and independence in work, home and social settings.

Charles Bonnet syndrome

Charles Bonnet syndrome is a term used to describe the phenomenon of visually impaired people seeing things that they know are not real. Visual hallucinations or phantom images can be extremely vivid and realistic and range from simple, repetitive patterns to detailed images of people, animals or buildings. About 30% of people who experience major vision loss experience this. The images are a consequence of losing sight whereby the brain attempts to compensate for the gaps in vision.

MDNZ resources

MDNZ has a range of publications and resources on MD and low vision.
Call MDNZ on 0800 MACULA (0800 622 852) for a free information kit.

Amsler Grid

This is an essential tool for self-monitoring of sudden changes in vision and possible symptoms of MD.

Macular Degeneration brochure

This fact sheet outlines the prevalence of MD, discusses barriers to treatment and the impact of MD on health, cost and rehabilitation.

Macular Degeneration Awareness DVD

This 17 minute DVD describes MD, its symptoms, risk factors, treatment options and the effects of MD, and includes interviews with people suffering from MD.

Low Vision Services DVD

This 11 minute DVD provides information about low vision services and available aids, with an emphasis on magnification, light and contrast plus practical advice about living day to day with MD.

What to ask your eye care professional brochure

This is a helpful resource to ensure you ask the right questions of an eye care professional in order to best understand your condition.

Nutrition and Supplements fact sheet

This fact sheet provides information on maximising macular health for those with MD as well as those seeking to reduce their risk of developing it.

Other resources

Blind Foundation

The Blind Foundation is a non-profit organisation and the main provider of vision-related services to the blind and those with low vision.

Phone: 0800 24 33 33

Web: www.blindfoundation.org.nz

Email: generalenquiries@blindfoundation.org.nz

Sight Loss Services

Sight Loss Services provides information, equipment and support to New Zealanders who have low vision, their families and others associated with people who have low vision.

Phone: 0800 555 546

Web: www.sightloss-services.com

Email: info@sightloss-services.com

Retina New Zealand

Retina NZ is a charitable organisation of and for people with retinal disorders that offers peer support and promotes education about causes, treatments and prevention of retinal degenerative conditions.

Phone: 0800 569 849

Web: www.retina.org.nz

Email: retina@retina.org.nz

Humanware

Humanware provide a range of advanced electronic magnifiers, Braille products, and digital talking book players that help people with blindness and low vision achieve independence.

Phone: 0508 225 5734

Web: www.humanware.com

Email: info@vahumanware.com

The Macular Disease Foundation Australia

The Macular Disease Foundation Australia offers several publications and resources on MD.

- Low Vision – A Guide
- Family, Friends and Carer – A Guide
- Low Vision Aids and Technology – A Guide
- Slips, Trips and Falls – A Guide
- Information in other languages
- Translated fact sheets

Phone: +61 2 9261 8900

Web: www.mdfoundation.com.au

Email: info@mdfoundation.com.au

Please donate to support those with MD

Title	Mr / Mrs / Ms / Miss / Other		
First name		Last name	
Name to appear on tax receipt			
Street address			
Suburb			
City		Postcode	
Email			
Phone (home)		(mobile)	

I would like to give a gift (choose one)

☐ Single ☐ Monthly ☐ Annually

Amount ☐ \$200 ☐ \$150 ☐ \$100 ☐ \$50 or \$

I would like to pay by (choose one)

☐ Cheque (enclosed)

☐ Credit card VISA / Mastercard (circle one)

Card number

Cardholder's name

Amount \$ Expiry date /

Signature

For online donations visit www.mdnz.org.nz

Thank you

- ☐ I would like to receive information about MD
- ☐ I would like to receive the MDNZ newsletter
- ☐ Please send me more information about leaving a gift/
bequest for MDNZ in my will

Please complete this form and return to

**Macular Degeneration New Zealand, PO Box 137070,
Parnell, Auckland 1151 or Fax 09 307 2021**

For assistance phone **0800 MACULA (0800 622 852)**



Donations over \$5 are tax deductible.




**MACULAR
DEGENERATION
NEW ZEALAND**

The Amsler Grid

This can be used to test for symptoms of Macular Degeneration



Normal vision



Consult your eye care professional immediately

Instructions:

- 1 Do not remove glasses or contact lenses normally used for reading.
- 2 Stand approximately 33cm from the grid in a well-lit room.
- 3 Cover one eye with your hand and focus on the centre dot with the uncovered eye. Repeat with the other eye.
- 4 If you see wavy, broken or distorted lines, or blurred or missing areas of vision, you may be displaying symptoms of Macular Degeneration and should contact your eye care professional immediately.

Key symptoms may include:

- Difficulty reading or with any activity that requires fine vision
- Distortion, where straight lines appear wavy or bent
- Difficulty distinguishing faces
- Dark patches or empty spaces in the centre of your vision
- The need for increased illumination, sensitivity to glare, decreased night vision and poor colour sensitivity may also indicate that something is wrong

Early detection of Macular Degeneration is crucial to saving sight

For more information phone the MDNZ helpline on

0800 MACULA (0800 622 852)

Do not depend on the Amsler Grid for diagnosis